{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:13:08Z","timestamp":1770682388419,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A \u201cmismatch\u201d sequence of less prenatal weight gain and more postnatal weight gain may lead to ectopic lipid accumulation, and trigger the development of early adrenarche\/pubarche and the activation of the gonadotropic axis resulting in early puberty and ending up in full-blown adolescent polycystic ovary syndrome (PCOS). In the present study, we assess whether a low-dose combination of generics that collectively reduce ectopic fat through different pathways can slow down the accelerated maturation in \u201cmismatch\u201d girls with early puberty.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Randomized, placebo-controlled, multicenter, phase 2a, study in 64 girls [age, 8.0\u20139.5 years; birthweight (BW) for gestational age: \u22122.5 &lt; <jats:italic>Z<\/jats:italic>-score &lt;0, body mass index (BMI): 0 &lt; <jats:italic>Z<\/jats:italic>-score &lt; +2.5 and early progressive puberty (Tanner B2 at 7.7\u20139.3 years)]. Pharmacological intervention will be with a half-dose version of SPIOMET (mini-spiomet), a combination that reverts the PCOS phenotype in \u201cmismatch\u201d adolescents; mini-spiomet will contain spironolactone (25 mg\/day, to raise brown adipose tissue activity), pioglitazone (3.75 mg\/day, to raise adiponectin and insulin sensitivity), and metformin (425 mg\/day, to raise AMPK activity and GDF15). Recruitment: 1 year; double-blind treatment: 1 year; open follow-up: 1 year; analyses and reporting: 1 year. Interventions: randomization (1:1) for placebo <jats:italic>vs<\/jats:italic> mini-spiomet. <jats:italic>Primary outcome<\/jats:italic>: annualized bone age advancement (0\u20131 year) by BoneXpert; <jats:italic>secondary outcomes<\/jats:italic>: insulin, IGF-I, high-molecular-weight adiponectin (HMW-adip), sex hormone binding globulin (SHBG), ultra-sensitive C-reactive protein (usCRP), androgens, luteinizing hormone (LH), follicle-stimulating hormone (FSH), oestradiol, growth-and-differentiation factor 15 (GDF15), C-X-C motif chemokine ligand-14 (CXCL14), safety parameters, and quantification of hepato-visceral fat.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The present study, if successful, may provide a first proof of the concept that the rapid maturation of girls with an upward mismatch between pre- and post-natal weight gain can be slowed down with a fixed low-dose combination of old and safe generics jointly targeting a reduction of ectopic fat without necessarily lowering body weight.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT 2021-006766-21. Registered on May 30, 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-07050-w","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T16:22:16Z","timestamp":1674577336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol"],"prefix":"10.1186","volume":"24","author":[{"given":"Judit","family":"Bassols","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"de Zegher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Carreras-Badosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Garcia-Beltran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Puerto-Carranza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cora","family":"Oliver-Vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Casano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line Alicia","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Malpique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel","family":"L\u00f3pez-Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4595-7191","authenticated-orcid":false,"given":"Lourdes","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"issue":"8","key":"7050_CR1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41574-020-0363-7","volume":"16","author":"VM Navarro","year":"2020","unstructured":"Navarro VM. Metabolic regulation of kisspeptin - the link between energy balance and reproduction. Nat Rev Endocrinol. 2020;16(8):407\u201320.","journal-title":"Nat Rev Endocrinol."},{"issue":"4","key":"7050_CR2","doi-asserted-by":"crossref","first-page":"e195881","DOI":"10.1001\/jamapediatrics.2019.5881","volume":"174","author":"C Eckert-Lind","year":"2020","unstructured":"Eckert-Lind C, Busch AS, Petersen JH, Biro FM, Butler G, Br\u00e4uner EV, et al. Worldwide secular trends in age at pubertal onset assessed by breast development among girls: a systematic review and meta-analysis. JAMA Pediatr. 2020;174(4):e195881.","journal-title":"JAMA Pediatr."},{"issue":"7693","key":"7050_CR3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature25750","volume":"554","author":"CM Worthman","year":"2018","unstructured":"Worthman CM, Trang K. Dynamics of body time, social time and life history at adolescence. Nature. 2018;554(7693):451\u20137.","journal-title":"Nature."},{"issue":"3943","key":"7050_CR4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.169.3943.397","volume":"169","author":"RE Frisch","year":"1970","unstructured":"Frisch RE, Revelle R. Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science. 1970;169(3943):397\u20139.","journal-title":"Science."},{"issue":"1","key":"7050_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S2352-4642(18)30306-7","volume":"3","author":"T Reinehr","year":"2019","unstructured":"Reinehr T, Roth CL. Is there a causal relationship between obesity and puberty? Lancet Child Adolesc Health. 2019;3(1):44\u201354.","journal-title":"Lancet Child Adolesc Health."},{"key":"7050_CR6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.coemr.2020.08.004","volume":"14","author":"A Huang","year":"2020","unstructured":"Huang A, Reinehr T, Roth CL. Connections between obesity and puberty: invited by manuel tena-sempere, cordoba. Curr Opin Endocr Metab Res. 2020;14:160\u20138.","journal-title":"Curr Opin Endocr Metab Res"},{"key":"7050_CR7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jpeds.2018.12.022","volume":"208","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Kwon A, Jung MK, Kim KE, Suh J, Chae HW, et al. Incidence and prevalence of central precocious puberty in korea: an epidemiologic study based on a national database. J Pediatr. 2019;208:221\u20138.","journal-title":"J Pediatr."},{"issue":"2","key":"7050_CR8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12020-021-02630-3","volume":"72","author":"Y Liu","year":"2021","unstructured":"Liu Y, Yu T, Li X, Pan D, Lai X, Chen Y, et al. Prevalence of precocious puberty among Chinese children: a school population-based study. Endocrine. 2021;72(2):573\u201381.","journal-title":"Endocrine."},{"issue":"1","key":"7050_CR9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12887-019-1703-4","volume":"19","author":"MK Jung","year":"2019","unstructured":"Jung MK, Choi HS, Suh J, Kwon A, Chae HW, Lee WJ, et al. The analysis of endocrine disruptors in patients with central precocious puberty. BMC Pediatr. 2019;19(1):323.","journal-title":"BMC Pediatr."},{"issue":"1","key":"7050_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13052-020-00931-3","volume":"46","author":"S Stagi","year":"2020","unstructured":"Stagi S, De Masi S, Bencini E, Losi S, Paci S, Parpagnoli M, et al. Increased incidence of precocious and accelerated puberty in females during and after the Italian lockdown for the coronavirus 2019 (COVID-19) pandemic. Ital J Pediatr. 2020;46(1):165.","journal-title":"Ital J Pediatr."},{"issue":"12","key":"7050_CR11","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/humrep\/deaa213","volume":"35","author":"LM O'Keeffe","year":"2020","unstructured":"O'Keeffe LM, Frysz M, Bell JA, Howe LD, Fraser A. Puberty timing and adiposity change across childhood and adolescence: disentangling cause and consequence. Hum Reprod. 2020;35(12):2784\u201392.","journal-title":"Hum Reprod."},{"issue":"7520","key":"7050_CR12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13545","volume":"514","author":"JR Perry","year":"2014","unstructured":"Perry JR, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature. 2014;514(7520):92\u20137.","journal-title":"Nature."},{"key":"7050_CR13","doi-asserted-by":"crossref","first-page":"180729","DOI":"10.1155\/2011\/180729","volume":"2011","author":"HS Mumby","year":"2011","unstructured":"Mumby HS, Elks CE, Li S, Sharp SJ, Khaw KT, Luben RN, et al. Mendelian randomisation study of childhood bmi and early menarche. J Obes. 2011;2011:180729.","journal-title":"J Obes."},{"issue":"6","key":"7050_CR14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/humupd\/dmx025","volume":"23","author":"MS Avenda\u00f1o","year":"2017","unstructured":"Avenda\u00f1o MS, Vazquez MJ, Tena-Sempere M. Disentangling puberty: novel neuroendocrine pathways and mechanisms for the control of mammalian puberty. Hum Reprod Update. 2017;23(6):737\u201363.","journal-title":"Hum Reprod Update."},{"issue":"6","key":"7050_CR15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.cmet.2020.10.001","volume":"32","author":"V Heras","year":"2020","unstructured":"Heras V, Castellano JM, Fernandois D, Velasco I, Rodr\u00edguez-Vazquez E, Roa J, et al. Central ceramide signaling mediates obesity-induced precocious puberty. Cell Metab. 2020;32(6):951\u2013966.e8.","journal-title":"Cell Metab."},{"key":"7050_CR16","doi-asserted-by":"crossref","first-page":"154460","DOI":"10.1016\/j.metabol.2020.154460","volume":"115","author":"D Franssen","year":"2021","unstructured":"Franssen D, Barroso A, Ruiz-Pino F, V\u00e1zquez MJ, Garc\u00eda-Galiano D, Castellano JM, et al. AMP-activated protein kinase (AMPK) signaling in GnRH neurons links energy status and reproduction. Metabolism. 2021;115:154460.","journal-title":"Metabolism."},{"issue":"1","key":"7050_CR17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm.2277","volume":"17","author":"WL Holland","year":"2011","unstructured":"Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med. 2011;17(1):55\u201363.","journal-title":"Nat Med."},{"issue":"12","key":"7050_CR18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.tem.2018.09.005","volume":"29","author":"F de Zegher","year":"2018","unstructured":"de Zegher F, L\u00f3pez-Bermejo A, Ib\u00e1\u00f1ez L. Central obesity, faster maturation, and 'pcos' in girls. Trends Endocrinol Metab. 2018;29(12):815\u20138.","journal-title":"Trends Endocrinol Metab."},{"issue":"3","key":"7050_CR19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ajg.2018.1","volume":"113","author":"GR Umano","year":"2018","unstructured":"Umano GR, Caprio S, Di Sessa A, Chalasani N, Dykas DJ, Pierpont B, et al. The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth. Am J Gastroenterol. 2018;113(3):376\u201383.","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"7050_CR20","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/jc.2005-2778","volume":"91","author":"L Ib\u00e1\u00f1ez","year":"2006","unstructured":"Ib\u00e1\u00f1ez L, Ong K, Dunger DB, de Zegher F. Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. J Clin Endocrinol Metab. 2006;91(6):2153\u20138.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"7050_CR21","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1210\/jc.2007-1618","volume":"93","author":"L Ib\u00e1\u00f1ez","year":"2008","unstructured":"Ib\u00e1\u00f1ez L, Su\u00e1rez L, Lopez-Bermejo A, D\u00edaz M, Valls C, de Zegher F. Early development of visceral fat excess after spontaneous catch-up growth in children with low birth weight. J Clin Endocrinol Metab. 2008;93(3):925\u20138.","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"7050_CR22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/ijpo.12053","volume":"11","author":"G Sebastiani","year":"2016","unstructured":"Sebastiani G, D\u00edaz M, Bassols J, Aragon\u00e9s G, L\u00f3pez-Bermejo A, de Zegher F, et al. The sequence of prenatal growth restraint and post-natal catch-up growth leads to a thicker intima-media and more pre-peritoneal and hepatic fat by age 3-6 years. Pediatr Obes. 2016;11(4):251\u20137.","journal-title":"Pediatr Obes."},{"issue":"3","key":"7050_CR23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2337\/db16-0776","volume":"66","author":"M D\u00edaz","year":"2017","unstructured":"D\u00edaz M, Garc\u00eda C, Sebastiani G, de Zegher F, L\u00f3pez-Bermejo A, Ib\u00e1\u00f1ez L. Placental and Cord Blood Methylation of Genes Involved in Energy Homeostasis: Association With Fetal Growth and Neonatal Body Composition. Diabetes. 2017;66(3):779\u201384.","journal-title":"Diabetes."},{"issue":"10","key":"7050_CR24","doi-asserted-by":"crossref","first-page":"e12533","DOI":"10.1111\/ijpo.12533","volume":"14","author":"F de Zegher","year":"2019","unstructured":"de Zegher F, Malpique R, Garcia-Beltran C, Ib\u00e1\u00f1ez L. Towards a simple marker of hepato-visceral adiposity and insulin resistance: The Z-score change from weight-at-birth to BMI-in-childhood. Pediatr Obes. 2019;14(10):e12533.","journal-title":"Pediatr Obes."},{"issue":"5","key":"7050_CR25","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/ije\/dyaa143","volume":"49","author":"YY Ong","year":"2020","unstructured":"Ong YY, Sadananthan SA, Aris IM, Tint MT, Yuan WL, Huang JY, et al. Mismatch between poor fetal growth and r\u00e0pid postnatal weight gain in the first 2 years of life is associated with higher blood pressure and insulin resistance without increased adiposity in childhood: the GUSTO cohort study. Int J Epidemiol. 2020;49(5):1591\u2013603.","journal-title":"Int J Epidemiol."},{"issue":"6","key":"7050_CR26","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1210\/jc.2003-031848","volume":"89","author":"KK Ong","year":"2004","unstructured":"Ong KK, Potau N, Petry CJ, Jones R, Ness AR, Honour JW, et al. Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab. 2004;89(6):2647\u201351.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"7050_CR27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1542\/peds.2005-0664","volume":"117","author":"L Ib\u00e1\u00f1ez","year":"2006","unstructured":"Ib\u00e1\u00f1ez L, Jim\u00e9nez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics. 2006;117(1):117\u201321.","journal-title":"Pediatrics."},{"issue":"10","key":"7050_CR28","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1210\/jc.2009-0789","volume":"94","author":"L Ib\u00e1\u00f1ez","year":"2009","unstructured":"Ib\u00e1\u00f1ez L, Lopez-Bermejo A, D\u00edaz M, Su\u00e1rez L, de Zegher F. Low-birth weight children develop lower sex hormone binding globulin and higher dehydroepiandrosterone sulfate levels and aggravate their visceral adiposity and hypoadiponectinemia between six and eight years of age. J Clin Endocrinol Metab. 2009;94(10):3696\u20139.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"7050_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1542\/peds.2013-0628","volume":"133","author":"S Mrug","year":"2014","unstructured":"Mrug S, Elliott MN, Davies S, Tortolero SR, Cuccaro P, Schuster MA. Early puberty, negative peer influence, and problem behaviors in adolescent girls. Pediatrics. 2014;133(1):7\u201314.","journal-title":"Pediatrics."},{"issue":"12","key":"7050_CR30","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00592-018-1214-z","volume":"55","author":"CJ Petry","year":"2018","unstructured":"Petry CJ, Ong KK, Dunger DB. Age at menarche and the future risk of gestational diabetes: a systematic review and dose response meta-analysis. Acta Diabetol. 2018;55(12):1209\u201319.","journal-title":"Acta Diabetol."},{"issue":"1","key":"7050_CR31","doi-asserted-by":"crossref","first-page":"e1003017","DOI":"10.1371\/journal.pmed.1003017","volume":"17","author":"TS Cheng","year":"2020","unstructured":"Cheng TS, Day FR, Lakshman R, Ong KK. Association of puberty timing with type 2 diabetes: A systematic review and meta-analysis. PLoS Med. 2020;17(1):e1003017.","journal-title":"PLoS Med."},{"issue":"6","key":"7050_CR32","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/ng.3841","volume":"49","author":"FR Day","year":"2017","unstructured":"Day FR, et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet. 2017;49(6):834\u201341.","journal-title":"Nat Genet."},{"issue":"2","key":"7050_CR33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/EJE-20-0862","volume":"184","author":"C Harbulot","year":"2021","unstructured":"Harbulot C, Lessim S, Simon D, Martinerie L, Storey C, Ecosse E, et al. Prevalence and clinical characteristics of isolated forms of central precocious puberty: a cohort study at a single academic center. Eur J Endocrinol. 2021;184(2):243\u201351.","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"7050_CR34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1210\/jc.2006-1378","volume":"92","author":"DM Sloboda","year":"2007","unstructured":"Sloboda DM, Hart R, Doherty DA, Pennell CE, Hickey M. Age at menarche: Influences of prenatal and postnatal growth. J Clin Endocrinol Metab. 2007;92(1):46\u201350.","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"7050_CR35","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1210\/jc.2008-0013","volume":"93","author":"L Ib\u00e1\u00f1ez","year":"2008","unstructured":"Ib\u00e1\u00f1ez L, L\u00f3pez-Bermejo A, D\u00edaz M, Marcos MV, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab. 2008;93(5):1841\u20135.","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"7050_CR36","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jpeds.2009.07.012","volume":"156","author":"L Ib\u00e1\u00f1ez","year":"2010","unstructured":"Ib\u00e1\u00f1ez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity. J Pediatr. 2010;156(1):98\u2013102.e1.","journal-title":"J Pediatr."},{"issue":"7","key":"7050_CR37","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/pedi.12220","volume":"16","author":"M D\u00edaz","year":"2015","unstructured":"D\u00edaz M, Bassols J, L\u00f3pez-Bermejo A, de Zegher F, Ib\u00e1\u00f1ez L. Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. Pediatr Diabetes. 2015;16(7):538\u201345.","journal-title":"Pediatr Diabetes."},{"issue":"2","key":"7050_CR38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000479369","volume":"89","author":"F de Zegher","year":"2018","unstructured":"de Zegher F, Garc\u00eda Beltr\u00e1n C, L\u00f3pez-Bermejo A, Ib\u00e1\u00f1ez L. Metformin for rapidly maturing girls with central adiposity: less liver fat and slower bone maturation. Horm Res Paediatr. 2018;89(2):136\u201340.","journal-title":"Horm Res Paediatr."},{"issue":"8","key":"7050_CR39","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1210\/jc.2006-0336","volume":"91","author":"L Ib\u00e1\u00f1ez","year":"2006","unstructured":"Ib\u00e1\u00f1ez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab. 2006;91(8):2888\u201391.","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"7050_CR40","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/jc.2005-2329","volume":"91","author":"L Ib\u00e1\u00f1ez","year":"2006","unstructured":"Ib\u00e1\u00f1ez L, Valls C, Ong K, Dunger DB, de Zegher F. Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab. 2006;91(6):2068\u201373.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"7050_CR41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.fertnstert.2010.08.052","volume":"95","author":"L Ib\u00e1\u00f1ez","year":"2011","unstructured":"Ib\u00e1\u00f1ez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil Steril. 2011;95(2):727\u201330.","journal-title":"Fertil Steril."},{"issue":"8","key":"7050_CR42","doi-asserted-by":"crossref","first-page":"E1262","DOI":"10.1210\/jc.2011-0555","volume":"96","author":"L Ib\u00e1\u00f1ez","year":"2011","unstructured":"Ib\u00e1\u00f1ez L, L\u00f3pez-Bermejo A, D\u00edaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011;96(8):E1262\u20137.","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"7050_CR43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jadohealth.2017.04.010","volume":"61","author":"L Ib\u00e1\u00f1ez","year":"2017","unstructured":"Ib\u00e1\u00f1ez L, Del R\u00edo L, D\u00edaz M, Sebastiani G, Pozo \u00d3J, L\u00f3pez-Bermejo A, et al. Normalizing ovulation rate by preferential reduction of hepato-visceral fat in adolescent girls with polycystic ovary syndrome. J Adolesc Health. 2017;61(4):446\u201353.","journal-title":"J Adolesc Health."},{"issue":"5","key":"7050_CR44","doi-asserted-by":"crossref","first-page":"bvaa032","DOI":"10.1210\/jendso\/bvaa032","volume":"4","author":"L Ib\u00e1\u00f1ez","year":"2020","unstructured":"Ib\u00e1\u00f1ez L, D\u00edaz M, Garc\u00eda-Beltr\u00e1n C, Malpique R, Garde E, L\u00f3pez-Bermejo A, et al. Toward a treatment normalizing ovulation rate in adolescent girls with polycystic ovary syndrome. J Endocr Soc. 2020;4(5):bvaa032.","journal-title":"J Endocr Soc."},{"issue":"4","key":"7050_CR45","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.31592","volume":"73","author":"F de Zegher","year":"2021","unstructured":"de Zegher F, Ib\u00e1\u0148ez L. Letter to the Editor: Tackling NAFLD in adolescent polycystic ovary syndrome: reducing liver fat to mimic weight loss. Hepatology. 2021;73(4):1623\u20134.","journal-title":"Hepatology."},{"issue":"1","key":"7050_CR46","doi-asserted-by":"crossref","first-page":"e000574","DOI":"10.1136\/bmjgast-2020-000574","volume":"8","author":"F de Zegher","year":"2021","unstructured":"de Zegher F, Diaz M, Iba\u00f1ez L. From adolescent PCOS to adult MAFLD: opposing effects of randomised interventions. BMJ Open Gastroenterol. 2021;8(1):e000574.","journal-title":"BMJ Open Gastroenterol."},{"issue":"3","key":"7050_CR47","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/dom.13539","volume":"21","author":"M Thuzar","year":"2019","unstructured":"Thuzar M, Law WP, Dimeski G, Stowasser M, Ho KKY. Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study. Diabetes Obes Metab. 2019;21(3):509\u201316.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"7050_CR48","doi-asserted-by":"crossref","first-page":"e001035","DOI":"10.1136\/bmjdrc-2019-001035","volume":"8","author":"C Garc\u00eda-Beltran","year":"2020","unstructured":"Garc\u00eda-Beltran C, Cereijo R, Quesada-L\u00f3pez T, Malpique R, L\u00f3pez-Bermejo A, de Zegher F, et al. Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization. BMJ Open Diabetes Res Care. 2020;8(1):e001035.","journal-title":"BMJ Open Diabetes Res Care."},{"key":"7050_CR49","unstructured":"Food and Drug Administration. Label information NDA n\u00b0 012151. Aldactone\u00ae.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/012151s075lbl.pdf."},{"issue":"9","key":"7050_CR50","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2013-1040","volume":"98","author":"MA Ganie","year":"2013","unstructured":"Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab. 2013;98(9):3599\u2013607.","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"7050_CR51","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","volume":"37","author":"RJ Biggar","year":"2013","unstructured":"Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol. 2013;37(6):870\u20135.","journal-title":"Cancer Epidemiol."},{"issue":"2","key":"7050_CR52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2265.2007.03137.x","volume":"68","author":"L Ib\u00e1\u00f1ez","year":"2008","unstructured":"Ib\u00e1\u00f1ez L, L\u00f3pez-Bermejo A, D\u00edaz M, Enr\u00edquez G, Valls C, de Zegher F. Pioglitazone (7.5 mg\/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clin Endocrinol (Oxf). 2008;68(2):317\u201320.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"7050_CR53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00125-020-05281-7","volume":"64","author":"U White","year":"2021","unstructured":"White U, Fitch MD, Beyl RA, Hellerstein MK, Ravussin E. Adipose depot-specific effects of 16 weeks of pioglitazone on in vivo adipogenesis in women with obesity: a randomised controlled trial. Diabetologia. 2021;64(1):159\u201367.","journal-title":"Diabetologia."},{"issue":"7305","key":"7050_CR54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi JH, Banks AS, Estall JL, Kajimura S, Bostr\u00f6m P, Laznik D, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature. 2010;466(7305):451\u20136.","journal-title":"Nature."},{"issue":"3","key":"7050_CR55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265\u201377.","journal-title":"JAMA."},{"issue":"9","key":"7050_CR56","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/dme.14053","volume":"36","author":"REJ Ryder","year":"2019","unstructured":"Ryder REJ, DeFronzo RA. Pioglitazone: inexpensive; very effective at reducing HbA1c; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit. Diabet Med. 2019;36(9):1185\u20136.","journal-title":"Diabet Med."},{"key":"7050_CR57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13229-018-0241-5","volume":"9","author":"L Capano","year":"2018","unstructured":"Capano L, Dupuis A, Brian J, Mankad D, Genore L, Hastie Adams R, et al. A pilot dose finding study of pioglitazone in autistic children. Mol Autism. 2018;9:59.","journal-title":"Mol Autism."},{"issue":"1","key":"7050_CR58","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","volume":"45","author":"RL Walsky","year":"2005","unstructured":"Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005;45(1):68\u201378.","journal-title":"J Clin Pharmacol."},{"issue":"7795","key":"7050_CR59","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444\u20138.","journal-title":"Nature."},{"issue":"1","key":"7050_CR60","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/s41598-021-81349-7","volume":"11","author":"M Yang","year":"2021","unstructured":"Yang M, Darwish T, Larraufie P, Rimmington D, Cimino I, Goldspink DA, et al. Inhibition of mitochondrial function by metformin increases glucose uptake, glycolysis and GDF-15 release from intestinal cells. Sci Rep. 2021;11(1):2529.","journal-title":"Sci Rep."},{"issue":"1","key":"7050_CR61","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41598-021-86317-9","volume":"11","author":"F de Zegher","year":"2021","unstructured":"de Zegher F, D\u00edaz M, Villarroya J, Cair\u00f3 M, L\u00f3pez-Bermejo A, Villarroya F, et al. The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat. Sci Rep. 2021;11(1):7018.","journal-title":"Sci Rep."},{"key":"7050_CR62","volume-title":"CPMP\/4082\/00. Referral for Metformin","author":"European Medicines Agency (EMA)","year":"2001","unstructured":"European Medicines Agency (EMA). CPMP\/4082\/00. Referral for Metformin. 2001."},{"issue":"8","key":"7050_CR63","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrendo.2014.58","volume":"10","author":"L Ib\u00e1\u00f1ez","year":"2014","unstructured":"Ib\u00e1\u00f1ez L, Ong KK, L\u00f3pez-Bermejo A, Dunger DB, de Zegher F. Hyperinsulinaemic androgen excess in adolescent girls. Nat Rev Endocrinol. 2014;10(8):499\u2013508.","journal-title":"Nat Rev Endocrinol."},{"issue":"19","key":"7050_CR64","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","volume":"321","author":"J Flory","year":"2019","unstructured":"Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926\u20137.","journal-title":"JAMA."},{"issue":"3","key":"7050_CR65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MAJ.0b013e3182a562b7","volume":"349","author":"FJ Pasquel","year":"2015","unstructured":"Pasquel FJ, Klein R, Adigweme A, Hinedi Z, Coralli R, Pimentel JL, et al. Metformin-associated lactic acidosis. Am J Med Sci. 2015;349(3):263\u20137.","journal-title":"Am J Med Sci."},{"issue":"6","key":"7050_CR66","doi-asserted-by":"crossref","first-page":"e100379","DOI":"10.1371\/journal.pone.0100379","volume":"9","author":"Q Liu","year":"2014","unstructured":"Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PLoS One. 2014;9(6):e100379.","journal-title":"PLoS One."},{"issue":"11","key":"7050_CR67","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2165\/11593970-000000000-00000","volume":"50","author":"D S\u00e1nchez-Infantes","year":"2011","unstructured":"S\u00e1nchez-Infantes D, D\u00edaz M, L\u00f3pez-Bermejo A, Marcos MV, de Zegher F, Ib\u00e1\u00f1ez L. Pharmacokinetics of metformin in girls aged 9 years. Clin Pharmacokinet. 2011;50(11):735\u20138.","journal-title":"Clin Pharmacokinet."}],"updated-by":[{"DOI":"10.1186\/s13063-023-07483-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000}}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-07050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-07050-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-07050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T02:16:24Z","timestamp":1700619384000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-07050-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7050"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-07050-w","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13063-023-07483-x","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"18 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13063-023-07483-x","URL":"https:\/\/doi.org\/10.1186\/s13063-023-07483-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be conducted in accordance with the principles of Good Clinical Practice. This study was accepted by the Clinical Research Ethics Committee of Josep Trueta Hospital. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"The model of consent form will be provided on request by sending an email to the corresponding author. The consent contains information about the purpose of the trial; the medication used in the study; data and sample collection and storage; potential benefits and risks; and the right to refuse participation or to withdraw consent at any time.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"56"}}